Obexelimab

奥贝利单抗

Report date: 2024/09/09 14:12:14

Base Information

Drug NameObexelimab
Drug Alias NameAnti-CD19 monoclonal antibody (Xencor)Humanised Fc-engineered monoclonal antibody against CD19 (Xencor)XmAb-5871AMG-729
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionB-lymphocyte antigen CD19 inhibitorsLow affinity immunoglobulin gamma Fc region receptor II-b modulators
TargetsB-lymphocyte antigen CD19Low affinity immunoglobulin gamma Fc region receptor II-b
Therapy Area/IndicationsImmunoglobulin G4-Related DiseaseLupus Erythematosus, SystemicAnemia, Hemolytic, Autoimmune +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[30] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesXencor Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyRoyalty Pharma PLCAmgen Inc +[5] 
Inactive CompaniesXencor Inc
Active IndicationsImmunoglobulin G4-Related DiseaseLupus Erythematosus, SystemicAnemia, Hemolytic, Autoimmune +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A